FDA Experts Are Still Puzzled Over Who Should Get Which Covid Shots and When

A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the Centers for Disease Control and Prevention to decide the best long-term strategy.

Florida Gov. DeSantis Falsely Claims Bivalent Booster Boosts Chances of Covid Infection

Experts say the Florida governor’s conclusion could not be drawn from the study he cited, adding that the research focused on health care workers, who are likelier to be exposed to covid and more likely to be vaccinated. Those findings should not be applied to the general public.

Adolescentes latinos se entrenan para educar sobre las vacunas contra covid

Organizaciones comunitarias de salud en California y en todo el país forman a adolescentes, muchos de ellos latinos, para que actúen como educadores de la salud en la escuela, en las redes sociales y en las comunidades donde persiste el miedo a la vacuna contra covid.

KHN’s ‘What the Health?’: The Covid Response Coordinator Speaks

In this special episode of KHN’s “What the Health?” Dr. Ashish Jha, the White House coronavirus response coordinator, talks with host Julie Rovner, KHN’s chief Washington correspondent, about where we are in the pandemic and how we should transition out of the public health emergency. This episode was taped on Dec. 20.

KHN’s ‘What the Health?’: Health Spending? Only Congress Knows

Top negotiators in Congress have agreed to a framework for government spending into next year, but there are details to iron out before a vote — such as the scheduled Medicare payment cuts that have providers worried. Also, the Biden administration reopens its program allowing Americans to request free covid-19 home tests, as hopes for pandemic preparedness measures from Congress dim. Rachel Cohrs of Stat, Alice Miranda Ollstein of Politico, and Rebecca Adams of KHN join KHN’s Mary Agnes Carey to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

Empresas de capital riesgo invierten en el negocio de los ensayos clínicos de medicamentos. ¿Cuál es el riesgo para los pacientes?

Para lanzar un nuevo fármaco al mercado, la Administración de Alimentos y Medicamentos (FDA) exige a las farmacéuticas estudios exhaustivos para demostrar su seguridad y eficacia. Conseguir que un medicamento salga al mercado unos meses antes, y con menos gastos de lo habitual, puede traducirse en beneficios millonarios para el fabricante.

KHN’s ‘What the Health?’: Medicaid Machinations

The lame-duck Congress has returned to Washington with a long health care to-do list and only a little time. Meanwhile, some of the states that have not yet expanded Medicaid eligibility under the Affordable Care Act are rethinking those decisions. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these topics and more. Also this week, Rovner interviews KHN’s Fred Clasen-Kelly, who reported and wrote the latest KHN-NPR “Bill of the Month” feature, about a mysterious mishap during minor surgery.